Corbus Pharmaceuticals, based in Norwood, Massachusetts, focuses on developing therapies for rare inflammatory diseases and cancer, with a pipeline including CRB-701 and CRB-601. The company went public on October 24, 2014, and employs 19 staff.
Corbus Pharmaceuticals Holdings (CRBP) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Corbus Pharmaceuticals Holdings's actual EPS was -$1.15, missing the estimate of -$0.97 per share, resulting in a -18.43% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
